Compare · BWAY vs MDLN
BWAY vs MDLN
Side-by-side comparison of BrainsWay Ltd. (BWAY) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BWAY and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $48.08B, about 101.4x BWAY ($474.3M).
- MDLN has been more active in the news (7 items in the past 4 weeks vs 3 for BWAY).
- MDLN has more recent analyst coverage (25 ratings vs 6 for BWAY).
- Company
- BrainsWay Ltd.
- Medline Inc.
- Price
- -
- -
- Market cap
- $474.3M
- $48.08B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2025
- News (4w)
- 3
- 7
- Recent ratings
- 6
- 25
BrainsWay Ltd.
Brainsway Ltd., a commercial stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. It offers deep transcranial magnetic stimulation technology for the treatment of major depressive disorders, obsessive-compulsive disorders, bipolar disorders, post traumatic stress disorders, schizophrenia, smoking cessation, Alzheimer's disease, Asperger syndromes, alcohol addictions, attention deficit hyperactivity disorders, Parkinson's disease, and chronic neuropathic pains to transmit electric current flows at varying rates and creating an electromagnetic field that serves to depolarize cortical neurons and activate neural networks in various areas of the brain. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
Latest BWAY
- SEC Form 6-K filed by BrainsWay Ltd.
- BrainsWay Reports Rise in Favorable Accelerated Deep TMS™ Coverage to Over 70 Million Covered Lives
- SEC Form 6-K filed by BrainsWay Ltd.
- SEC Form 6-K filed by BrainsWay Ltd.
- BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer’s Disease Treated with Deep TMS™
- SEC Form 6-K filed by BrainsWay Ltd.
- BrainsWay Deep TMS™ Study Shows 70% Reduction in Patients Experiencing Suicidal Ideation
- SEC Form 6-K filed by BrainsWay Ltd.
- SEC Form 6-K filed by BrainsWay Ltd.
- BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
Latest MDLN
- SEC Form 8-K filed by Medline Inc.
- Medline to build Midwestern network with new 800,000-square-foot facility in Van Buren Township, Mich.
- SEC Form 4 filed by Medline Inc.
- Medline launches enhanced TrackPoint™ to simplify inventory management for post-acute care
- SEC Form 4 filed by Medline Inc.
- MEDLINE INC. MDLN INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 12.8% Share Drop
- Medline to report third quarter 2026 results on November 4, 2026
- INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Medline Inc. to Contact Law Firm
- Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
- SEC Form 4 filed by Chief Executive Officer Boyle James M